Search

Pharma

Value

To be able to find the right path for the introduction of a medicine in Italy, it is necessary to explore and translate the map of the regulatory environment, identifying and analysing the expectations and reports of decision-makers.

We assist those who turn to us in understanding and obtaining a fair price and reimbursement for a medicine. Finding a common ground, by appropriately mediating between Company profit, patient needs and the limited resources of the National Health Service, is a victory for all interest groups involved.
Through the years, we have learnt that the reality of things is more complex than whatever had been planned.
Even when everything is well-prepared and strategies corresponding to the value of the medicine, in accordance with the regulatory objectives of the agencies, and accommodating to drug governance guidelines, are proposed, the pathway to the authorisation of a medicine may well progress differently than expected. Not to mention any external variables that could slow down, if not hinder, the access of a medicine to the market.
Integrated skills are needed to help with navigation
Though quite detailed, the map we have provided cannot define the complexity of the terrain. Our experience comes to the aid when it is not clear.
  • All
  • Scenario analysis
  • Notes
  • Drug Policy
  • Rare Diseases
  • Mapping
  • Team Pharma Value
All
  • All
  • Scenario analysis
  • Notes
  • Drug Policy
  • Rare Diseases
  • Mapping
  • Team Pharma Value
AIFA Drug Policy

New AIFA Regulation

On December 14th, 2022, a draft of the interministerial decree for the new AIFA regulation was shared by 'Quotidiano Sanità,' and on ...
Drug Agency Scenario analysis

New postponement of AIFA Commission renewal

It was approved last night, in the Council of Ministers of Wednesday 27 September 2023, as part of the Urgent Provisions on the extension ...
unconventional team building 23 Team Pharma Value

Unconventional Team building, 2nd edition

Here we go again! Once again this year Pharma Value wanted to share its team building with a partner company, More than Access - MTA, a company ...
AIFA meets' event Scenario analysis

AIFA meets

On 12 September, the 'AIFA Incontra' initiative was held at the agency's institutional headquarters in Via del Tritone, a new way of communicating with the ...
Notes

Pharma Value at the 2nd GIRF Congress - ISPOR Group Rome for Future

On 3 and 4 July, the 2nd GIRF Congress - ISPOR Roma for Future Group - was held in Milan, ...
Notes

From Horizon scanning to the new HTA Regulation

New regulations in the legislative landscape impose a high focus on access to medicines in the near future. As of 1 January 2025, it will become operational ...
Drug Policy

Special on Commission No. 3

For our colleagues outside Italy who watch us with attention and amazement, we are here to translate for you what is happening ...
Notes

Pharma Value analysis of the National Rare Disease Plan 2023-2026 - focus drugs

On Monday, 24 May 2023, at the State-Regions Conference, the approval of the National Plan for Rare Diseases 2023-2026 was ratified, after seven years of ...
special 3 on DM AIFA Scenario analysis

Special Commission Update No. 3 - Towards the reform of the governance of the Italian Medicines Agency and the Single Commission: where are we?

Update 20 November 2023 The extraordinary State-Regions Conference held on 16 November 2023, sanctioned the long-awaited agreement on the draft regulation of the ...
article cover customer feedback Team Pharma Value

What they say about us, first results of our customer feedback request

As of January 2023, Pharma Value started, in cooperation with the soc. coop. Prospects, a work of evaluation and analysis ...
en_GB